WallStSmart

Boston Scientific Corp (BSX)vsSandisk Corp (SNDK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 125% more annual revenue ($20.07B vs $8.93B). BSX leads profitability with a 14.4% profit margin vs -11.7%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

SNDK

Hold

49

out of 100

Grade: D+

Growth: 7.3Profit: 5.0Value: 5.0Quality: 8.0
Piotroski: 4/9Altman Z: 1.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.1%)

Margin of Safety

+1.1%

Fair Value

$70.25

Current Price

$69.48

$0.77 discount

UndervaluedFair: $70.25Overvalued

Intrinsic value data unavailable for SNDK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$103.10B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

SNDK5 strengths · Avg: 9.8/10
Operating MarginProfitability
35.5%10/10

Strong operational efficiency at 35.5%

Revenue GrowthGrowth
61.2%10/10

Revenue surging 61.2% year-over-year

EPS GrowthGrowth
618.0%10/10

Earnings expanding 618.0% YoY

Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Market CapQuality
$104.75B9/10

Large-cap with strong market position

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
36.0x4/10

Premium valuation, high expectations priced in

SNDK4 concerns · Avg: 2.8/10
Price/BookValuation
10.3x4/10

Trading at 10.3x book value

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
-9.4%2/10

ROE of -9.4% — below average capital efficiency

Profit MarginProfitability
-11.7%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : SNDK

The strongest argument for SNDK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 61.2% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : SNDK

The primary concerns for SNDK are Price/Book, Altman Z-Score, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a growth stock while SNDK is a hypergrowth play — different risk/reward profiles.

SNDK is growing revenue faster at 61.2% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 49/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Sandisk Corp

TECHNOLOGY · COMPUTER HARDWARE · USA

Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.

Visit Website →

Want to dig deeper into these stocks?